190 related articles for article (PubMed ID: 32180251)
1. IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
Terashima T; Honda M; Toyama T; Shimakami T; Shimizu R; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
J Gastroenterol Hepatol; 2020 Oct; 35(10):1813-1820. PubMed ID: 32180251
[TBL] [Abstract][Full Text] [Related]
2. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
Saeki I; Yamasaki T; Tanabe N; Iwamoto T; Matsumoto T; Urata Y; Hidaka I; Ishikawa T; Takami T; Yamamoto N; Uchida K; Terai S; Sakaida I
PLoS One; 2015; 10(5):e0126649. PubMed ID: 25992784
[TBL] [Abstract][Full Text] [Related]
3. Hepatic arterial infusion chemotherapy in combination with pegylated interferon-α-2b for advanced hepatocellular carcinoma.
Okita K; Yamasaki T; Hamabe S; Saeki I; Harima Y; Terai S; Sakaida I
Hepatogastroenterology; 2012; 59(114):533-7. PubMed ID: 22353519
[TBL] [Abstract][Full Text] [Related]
4. Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C.
Hodo Y; Honda M; Tanaka A; Nomura Y; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Sakai A; Sasaki M; Nakanuma Y; Moriyama M; Kaneko S
Clin Cancer Res; 2013 Apr; 19(7):1827-37. PubMed ID: 23426277
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification.
Miyaki D; Aikata H; Honda Y; Naeshiro N; Nakahara T; Tanaka M; Nagaoki Y; Kawaoka T; Takaki S; Waki K; Hiramatsu A; Takahashi S; Ishikawa M; Kakizawa H; Awai K; Chayama K
J Gastroenterol Hepatol; 2012 Dec; 27(12):1850-7. PubMed ID: 23020312
[TBL] [Abstract][Full Text] [Related]
6. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
[TBL] [Abstract][Full Text] [Related]
7. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC
Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061
[TBL] [Abstract][Full Text] [Related]
9. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
Lee BH; Lee DS; Cho CW; Yun SS
World J Surg Oncol; 2019 Aug; 17(1):143. PubMed ID: 31416447
[TBL] [Abstract][Full Text] [Related]
10. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan.
Nouso K; Miyahara K; Uchida D; Kuwaki K; Izumi N; Omata M; Ichida T; Kudo M; Ku Y; Kokudo N; Sakamoto M; Nakashima O; Takayama T; Matsui O; Matsuyama Y; Yamamoto K;
Br J Cancer; 2013 Oct; 109(7):1904-7. PubMed ID: 24008659
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Yamasaki T; Kimura T; Kurokawa F; Aoyama K; Ishikawa T; Tajima K; Yokoyama Y; Takami T; Omori K; Kawaguchi K; Tsuchiya M; Terai S; Sakaida I; Okita K
J Gastroenterol; 2005 Jan; 40(1):70-8. PubMed ID: 15692792
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
[TBL] [Abstract][Full Text] [Related]
13. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
[TBL] [Abstract][Full Text] [Related]
14. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.
Kim BK; Park JY; Choi HJ; Kim DY; Ahn SH; Kim JK; Lee DY; Lee KH; Han KH
J Cancer Res Clin Oncol; 2011 Apr; 137(4):659-67. PubMed ID: 20552225
[TBL] [Abstract][Full Text] [Related]
15. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Lyu N; Wang X; Li JB; Lai JF; Chen QF; Li SL; Deng HJ; He M; Mu LW; Zhao M
J Clin Oncol; 2022 Feb; 40(5):468-480. PubMed ID: 34905388
[TBL] [Abstract][Full Text] [Related]
16. [Hepatic arterial infusion chemotherapy (HAIC)--hepatocellular carcinoma].
Osuga K; Murakami T; Nakata S; Tomoda K; Nagano H; Monden M; Nakamura H
Gan To Kagaku Ryoho; 2004 Dec; 31(13):2114-7. PubMed ID: 15628754
[TBL] [Abstract][Full Text] [Related]
17. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
Niizeki T; Sumie S; Torimura T; Kurogi J; Kuromatsu R; Iwamoto H; Aino H; Nakano M; Kawaguchi A; Kakuma T; Sata M
J Gastroenterol; 2012 Jun; 47(6):686-95. PubMed ID: 22382631
[TBL] [Abstract][Full Text] [Related]
18. Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
Tsai WL; Lai KH; Liang HL; Hsu PI; Chan HH; Chen WC; Yu HC; Tsay FW; Wang HM; Tsai HC; Cheng JS
PLoS One; 2014; 9(5):e92784. PubMed ID: 24824520
[TBL] [Abstract][Full Text] [Related]
19. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.
Woo HY; Bae SH; Park JY; Han KH; Chun HJ; Choi BG; Im HU; Choi JY; Yoon SK; Cheong JY; Cho SW; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
Cancer Chemother Pharmacol; 2010 Jan; 65(2):373-82. PubMed ID: 19763572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
